Comparison can be verified through clinical study results and public health reports

Health Canada Approves Moderna's Updated COVID-19 Vaccine Targeting KP.2 Variant for Ages Six Months and Older

Sep 17, 2024, 03:06 PM

Health Canada has approved Moderna's updated COVID-19 vaccine targeting the KP.2 variant of SARS-CoV-2 for ages six months and older. This approval follows the FDA's authorization of three updated vaccines, including Pfizer-BioNTech, Moderna, and Novavax, which received FDA authorization in August. The Moderna vaccine, known as Spikevax, is expected to be available soon at major retailers such as RiteAid, Costco, CVS, Walgreens, and Walmart. Studies indicate that Novavax, a protein-based vaccine, has fewer side effects compared to mRNA vaccines like Moderna. Novavax reduces viral load by 600x, while Moderna reduces it by 100x.